Sunday 18 October 2026
Export VANI’s income statement to Excel — free account
Vivani Medical, Inc.
VANI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.7% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.12
0.03
−2.61%
Follow VANI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(265.02%) | (159.62%) | (176.41%) | (220.40%) | |
| (76.61%) | (65.74%) | (69.63%) | (74.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36,656.34%) | (187.72%) | (154.56%) | (147.61%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | (0.41) | (0.33) | (0.30) | |
Free Cash Flow |
(24.61) | (25.49) | (26.52) | (26.50) | |
Capital Expenditures |
(1.19) | (1.17) | (1.17) | (1.20) | |
| Other line items | |||||
Cash ROIC |
(625.04%) | (79.76%) | (68.30%) | (68.19%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.91 | 0.94 | 0.96 | |
Depreciation/Fixed assets |
0.15 | 0.15 | 0.16 | 0.17 | |
Capex/Depreciation |
(3.00) | (2.77) | (2.59) | (2.51) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.39) | (0.31) | (0.29) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates